Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) EBITDA Margin (2016 - 2025)

Anaptysbio filings provide 10 years of EBITDA Margin readings, the most recent being 66.06% for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 15501.0% year-over-year to 66.06%, compared with a TTM value of 7.75% through Dec 2025, up 24011.0%, and an annual FY2025 reading of 5.78%, up 15212.0% over the prior year.
  • EBITDA Margin hit 66.06% in Q4 2025 for Anaptysbio, up from 30.33% in the prior quarter.
  • The five-year high for EBITDA Margin was 66.06% in Q4 2025, with the low at 3945.05% in Q1 2022.
  • Median EBITDA Margin over the past 5 years was 437.45% (2024), compared with a mean of 1040.02%.
  • The largest YoY upside for EBITDA Margin was 272732bps in 2022 against a maximum downside of -376235bps in 2022.
  • Year by year, EBITDA Margin stood at 3240.36% in 2021, then surged by 84bps to 513.04% in 2022, then rose by 12bps to 451.5% in 2023, then skyrocketed by 80bps to 88.95% in 2024, then soared by 174bps to 66.06% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 66.06%, 30.33%, and 174.27% for Q4 2025, Q3 2025, and Q2 2025 respectively.